Research progress of A-kinase-anchoring protein mediated regulation of cardiac hypertrophy

Abstract

Abstract:

Cardiac hypertrophy is the compensatory response of the heart in response to stimulation. Cardiac hypertrophy can improve the physiological function of the heart, but pathological myocardiac hypertrophy can cause a series of adverse effects on the heart such as arrhythmia, heart failure and sudden death risk. Recent studies revealed that AKAPs participates in the regulation of pathological myocardiac hypertrophy with multiple signal factors. Here we review the role of the A-kinase anchoring protein (AKAPs) in the regulation of pathological hypertrophy and its clinical significance.

Key words: A-kinase-anchoring protein, myocardiac hypertrophy, mAKAP, AKAP121, AKAP-Lbc

CLC Number:

R542.2

WANG Zheng, WANG Hegui. Research progress of A-kinase-anchoring protein mediated regulation of cardiac hypertrophy[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(11): 1304-1308.

References

［1］Riaz S, Zeidan A, Mraiche F. Myocardial proteases and cardiac remodeling［J］. J Cell Physiol, 2017, 232(12): 3244-3250.
［2］Zhao L, Wu D, Sang M, et al. Stachydrine ameliorates isoproterenol-induced cardiac hypertrophy and fibrosis by suppressing inflammation and oxidative stress through inhibiting NF-kappaB and JAK/STAT signaling pathways in rats［J］. Int Immunopharmacol, 2017, 48: 102-109.
［3］Welch EJ, Jones BW, Scott JD. Networking with AKAPs: context-dependent regulation of anchored enzymes［J］. Mol Interv, 2010, 10(2): 86-97.
［4］Pawson CT, Scott JD. Signal integration through blending, bolstering and bifurcating of intracellular information［J］. Nat Struct Mol Biol, 2010, 17(6): 653-658.
［5］Scott JD, Dessauer CW, Tasken K. Creating order from chaos: cellular regulation by kinase anchoring［J］. Annu Rev Pharmacol Toxicol, 2013, 53: 187-210.
［6］Diviani D, Maric D, Perez Lopez I, et al. A-kinase anchoring proteins: molecular regulators of the cardiac stress response［J］. Biochim Biophys Acta, 2013, 1833(4): 901-908.
［7］Skroblin P, Grossmann S, Schafer G, et al. Mechanisms of protein kinase A anchoring［J］. Int Rev Cell Mol Biol, 2010, 283: 235-330.
［8］Beene DL, Scott JD. A-kinase anchoring proteins take shape［J］. Curr Opin Cell Biol, 2007, 19(2): 192-198.
［9］Carnegie GK, Burmeister BT. A-kinase anchoring proteins that regulate cardiac remodeling［J］. J Cardiovasc Pharmacol, 2011, 58(5): 451-458.
［10］Abrenica B, Alshaaban M, Czubryt MP. The A-kinase anchor protein AKAP121 is a negative regulator of cardiomyocyte hypertrophy［J］. J Mol Cell Cardiol, 2009, 46(5): 674-681.
［11］Carnegie GK, Soughayer J, Smith FD, et al. AKAP-Lbc mobilizes a cardiac hypertrophy signaling pathway［J］. Mol Cell, 2008, 32(2): 169-179.
［12］ Perez Lopez I, Cariolato L, Maric D, et al. A-kinase anchoring protein Lbc coordinates a p38 activating signaling complex controlling compensatory cardiac hypertrophy［J］. Mol Cell Biol, 2013, 33(15): 2903-2917.
［13］Kritzer MD, Li J, Passariello CL, et al. The scaffold protein muscle A-kinase anchoring protein beta orchestrates cardiac myocyte hypertrophic signaling required for the development of heart failure［J］. Circ Heart Fail, 2014, 7(4): 663-672.
［14］Scott JD, Pawson T. Cell signaling in space and time: where proteins come together and when they're apart［J］. Science, 2009, 326(5957): 1220-1224.
［15］Rababa'h A, Craft JW Jr, Wijaya CS, et al. Protein kinase A and phosphodiesterase-4D3 binding to coding polymorphisms of cardiac muscle anchoring protein (mAKAP)［J］. J Mol Biol, 2013, 425(18): 3277-3288.
［16］Passariello CL, Li J, Dodge-Kafka K, et al. mAKAP-a master scaffold for cardiac remodeling［J］. J Cardiovasc Pharmacol, 2015, 65(3): 218-225.
［17］Zhang L, Malik S, Pang J, et al. Phospholipase Cepsilon hydrolyzes perinuclear phosphatidylinositol 4-phosphate to regulate cardiac hypertrophy［J］. Cell, 2013, 153(1): 216-227.
［18］Xie M, Hill JA. HDAC-dependent ventricular remodeling［J］. Trends Cardiovasc Med, 2013, 23(6): 229-235.
［19］Liu Q, Hofmann PA. Protein phosphatase 2A-mediated cross-talk between p38 MAPK and ERK in apoptosis of cardiac myocytes［J］. Am J Physiol Heart Circ Physiol, 2004, 286(6): H2204-H2212.
［20］Dodge-Kafka KL, Kapiloff MS. The mAKAP signaling complex: integration of cAMP, calcium, and MAP kinase signaling pathways［J］. Eur J Cell Biol, 2006, 85(7): 593-602.
［21］Li J, Kritzer MD, Michel JJ, et al. Anchored p90 ribosomal S6 kinase 3 is required for cardiac myocyte hypertrophy［J］. Circ Res, 2013, 112(1): 128-139.
［22］Martinez EC, Passariello CL, Li J, et al. RSK3: A regulator of pathological cardiac remodeling［J］. IUBMB Life, 2015, 67(5): 331-337.
［23］Cavin S, Maric D, Diviani D. A-kinase anchoring protein-Lbc promotes pro-fibrotic signaling in cardiac fibroblasts［J］. Biochim Biophys Acta, 2014, 1843(2): 335-345.
［24］ Cariolato L, Cavin S, Diviani D. A-kinase anchoring protein (AKAP)-Lbc anchors a PKN-based signaling complex involved in alpha1-adrenergic receptor-induced p38 activation［J］. J Biol Chem, 2011, 286(10): 7925-7937.
［25］Marber MS, Rose B, Wang Y. The p38 mitogen-activated protein kinase pathway--a potential target for intervention in infarction, hypertrophy, and heart failure［J］. J Mol Cell Cardiol, 2011, 51(4): 485-490.
［26］Streicher JM, Ren S, Herschman H, et al. MAPK-activated protein kinase-2 in cardiac hypertrophy and cyclooxygenase-2 regulation in heart［J］. Circ Res, 2010, 106(8): 1434-1443.
［27］Del Vescovo CD, Cotecchia S, Diviani D. A-kinase-anchoring protein-Lbc anchors IkappaB kinase beta to support interleukin-6-mediated cardiomyocyte hypertrophy［J］. Mol Cell Biol, 2013, 33(1): 14-27.
［28］Smith FD, Scott JD. A-kinase-anchoring protein-Lbc connects stress signaling to cardiac hypertrophy［J］. Mol Cell Biol, 2013, 33(1): 2-3.
［29］Spindler MJ, Burmeister BT, Huang Y, et al. AKAP13 Rho-GEF and PKD-binding domain deficient mice develop normally but have an abnormal response to beta-adrenergic-induced cardiac hypertrophy［J］. PLoS One, 2013, 8(4): e62705.
［30］Taglieri DM, Johnson KR, Burmeister BT, et al. The C-terminus of the long AKAP13 isoform (AKAP-Lbc) is critical for development of compensatory cardiac hypertrophy［J］. J Mol Cell Cardiol, 2014, 66: 27-40.
［31］Johnson KR, Nicodemus-Johnson J, Spindler MJ, et al. Genome-wide gene expression analysis shows AKAP13-mediated PKD1 signaling regulates the transcriptional response to cardiac hypertrophy［J］. PLoS One, 2015, 10(7): e0132474.
［32］Barry SP, Townsend PA. What causes a broken heart-molecular insights into heart failure［J］. Int Rev Cell Mol Biol, 2010, 284: 113-179.
［33］Edwards HV, Scott JD, Baillie GS. The A-kinase-anchoring protein AKAP-Lbc facilitates cardioprotective PKA phosphorylation of Hsp20 on Ser(16)［J］. Biochem J, 2012, 446(3): 437-443.
［34］Schiattarella GG, Cattaneo F, Pironti G, et al. Akap1 deficiency promotes mitochondrial aberrations and exacerbates cardiac injury following permanent coronary ligation via enhanced mitophagy and apoptosis［J］. PLoS One, 2016, 11(5): e0154076.

[1]	HAO Xiao, ZHAO Mei, WANG Wenjing, ZHANG Feifei, LIU Huiliang, DANG Yi, LI Shuren, QI Xiaoyong. Application of sodium-glucose cotransporter 2 inhibitors in acute myocardial infarction [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 824-831.
[2]	CHEN Manxin, ZHANG Bingyu, DAI Min. Clinical efficacy of intracoronally targeted recombinant human urokinase combined with percutaneous coronary intervention (PCI) in acute myocardial infarction (AMI) with high thrombus burden [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 544-549.
[3]	PENG Juan, LI Ranyi, FAN Linlin, LI Xiaoyu, LV Qianzhou, ZOU Yunzeng. Progress of pharmacotherapy for myocardial hypertrophy and cardiac remodeling [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 382-389.
[4]	XIE Mengdie, WANG Chenchen, LI Bingtao, OUYANG Changsheng, QIU Yumei, LI Hongming, TU Jun, SHANG Guangbin, TANG Xilan. Analysis on mechanism of frankincense volatile oil in prevention and treatment of cardiac hypertrophy based on in vitro cell experiment and network pharmacology [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 241-252.
[5]	FU Xiaomei, HUO Ran, DENG Sai, LIN Chaojin, FAN Jinghao, WANG Ping, LI Songpei, QIN Aiping, ZOU Minghui, YU Xiyong. Exosomes derived from LPS-stimulated bone marrow mesenchymal stem cell improve myocardial inflammation and fibrosis after myocardial infarction in mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(8): 841-851.
[6]	ZHUO Fengqiao, HUANG Zhanhong, LIU Yujie. Protective effect of Liquiritigenin on H9C2 cardiomyocytes apoptosis induced by high glucose [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(2): 147-151.
[7]	ZONG Qiao-feng, CHENG Xiang-yang, YU Ying, ZHANG Wei-ping, GAO Qin, LI Zheng-hong. Experimental study of endomorphin-1 postconditioning against myocardial ischemia reperfusion injury in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(2): 132-137.
[8]	ZHOU Yong, HUANG Song-qun, XU Fei. Efficacy on slow bleeding and safety of using tirofiban before and during emergency PCI in patients with acute ST-segment elevation myocardial infarction [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(11): 1268-1271.
[9]	PAN Da-bin, WANG Min-hui, CAO Heng. Research progress of pathogenesis of diabetic cardiomyopathy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(7): 831-836.
[10]	CHEN Gao-yong, ZHANG Yan-mei, SHI Gang-gang. Effects of extracellular-signal regulated kinsae signaling pathway on myocardial ischemia/reperfusion injury [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(2): 234-240.
[11]	DENG Shao-xiong, GUO Nan-ou, ZHENG-Yuan, HUANG Wen-sen. Effect and clinical significance of tirofiban on serum matrix metalloproteinase 9 after primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction and diabetes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(7): 807-811.
[12]	BAI Xia, GUO Zhi-hong, ZHANG Fan, FAN Shu-duo. Effects of short-term fasting on energy metabolism and arrhythmia after myocardial ischemia/reperfusion in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(8): 900-905.
[13]	TANG Yuan-yuan, TANG Bo-jian, YAN Xiao-wei, FANG Quan. Clinical features and prognosis of obstructive and non-obstructive hypertrophic cardiomyopathy patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(2): 195-198.
[14]	XIE Ming-Ming, WANG Xin-Fang, ZHU Xiang-Ming, YANG Ya, LU Qing, CHEN Li-Xin, NIE Shao-Ping, JIANG Jue-Quan, CAO Lin-Shen. Effects of transmyocardial laser revascularization combined with basic fibroblast growth factor on myocardial viability and cardiac function in dog models with acute myocardial ischemia¹ [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2003, 8(2): 149-154.
[15]	FANG Wu-Wang, YAN Yue-Ying, DUAN Bao-Xiang. Analysis of endothelin receptor and its subtypes in the left ventricle of rats with dilated cardiomyopathy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2001, 6(4): 322-325.